Skip to content

Clinical trial of the second level prevention of liver cancer based on “tonifying the kidney to promote liver regeneration and repair by affecting stem cells and their microenvironment”

Clinical trial of the second level prevention of liver cancer based on “tonifying the kidney to promote liver regeneration and repair by affecting stem cells and their microenvironment”

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-17011438
Enrollment
Unknown
Registered
2017-05-19
Start date
2017-06-01
Completion date
Unknown
Last updated
2017-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cancer

Interventions

Control group :Western medicine comprehensive treatment
Treatment group:Comprehensive treatment based on the modified prescription of Diwu Yanggan and Kangdu Ruanjian

Sponsors

Hubei Provincial Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Patients with the first redical resection of small liver cancer; (2) Patients with a history of viral hepatitis; (3) The age over 18 years old.

Exclusion criteria

Exclusion criteria: (1) Patients were diagnosed as liver cancer, serious disease of cardiovascular and cerebrovascular diseases, lung, kidney, endocrine and hematopoietic system,or mental illness; (2) Women who have been pregnant or are prepared for pregnancy, or women in lactation; (3) Patients with allergic constitution, or allergic to a variety of drugs; (4) Patients with various factors affecting the data collection; (5) Patients cannot cooperate and (or) not willing to cooperate.

Design outcomes

Primary

MeasureTime frame
Recurrence rate and metastasis rate of liver cancer;

Secondary

MeasureTime frame
Liver function;Hepatitis B virus DNA;Hepatitis B virus maker;

Countries

China

Contacts

Public ContactHanmin Li

Hubei Provincial Hospital of Traditional Chinese Medicine

lihanmin69@126.com+86 027-88929180

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026